A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2015
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 Jun 2015 Status changed from active, no longer recruiting to completed ClinicalTrials.gov.
- 10 Nov 2014 Planned number of patients changed from 0 to 1, according to the ClinicalTrials.gov record.
- 11 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.